Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
ACC's initiative for health care reform

ACC's initiative for health care reform

Diabetes decreases cognitive decline in people with Alzheimer's disease

Diabetes decreases cognitive decline in people with Alzheimer's disease

Innovative approach to build a new drug to treat a number of CNS diseases

Innovative approach to build a new drug to treat a number of CNS diseases

Diabetics who are nearsighted may be less susceptible to diabetic retinopathy

Diabetics who are nearsighted may be less susceptible to diabetic retinopathy

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

Scientists discover new way to help save lives threatened by traumatic injuries

Scientists discover new way to help save lives threatened by traumatic injuries

Study: High protein levels are associated with heart attack and not stroke

Study: High protein levels are associated with heart attack and not stroke

Study shows diabetics who are nearsighted may be less susceptible to diabetic retinopathy

Study shows diabetics who are nearsighted may be less susceptible to diabetic retinopathy

Los Angeles Jewish Home continues to meet nursing shortage in the country

Los Angeles Jewish Home continues to meet nursing shortage in the country

Eurogentec to acquire Anaspec, a private proteomics company in California

Eurogentec to acquire Anaspec, a private proteomics company in California

Brain inflammation not linked to Alzheimer's disease

Brain inflammation not linked to Alzheimer's disease

Alzheimer's Association appreciates RCN for its generous donation and awareness campaign

Alzheimer's Association appreciates RCN for its generous donation and awareness campaign

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical establishes ESI as a wholly owned subsidiary

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Alzheimer's Association Comfort Zone launched

Alzheimer's Association Comfort Zone launched

Blood test to identify MCI patients at risk of Alzheimer's disease

Blood test to identify MCI patients at risk of Alzheimer's disease

Eyes may mirror Alzheimer's disease

Eyes may mirror Alzheimer's disease

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

On-line portal for training doctors and nurses on fall prevention and protection

On-line portal for training doctors and nurses on fall prevention and protection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.